AllDocs -> cancers

Cancer Incidence by Remoteness Category in Queensland Uterine cancer 0 5 10 15 20 25 30 Rate per 100,000 population Avg No. per Year Incidence of Uterine cancer among Females, by ARIA+ Category, Queensland, Five Year Average, 1998 to 2002 16.2 151 Major City ARIAplus Category 16.6 85 Inner Regional 14.5 41 Outer Regional 16.1 3 Remote 13.9 2 Very remote Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 . Source: ...

Trends in Cancer Mortality by Health Zone in Queensland Uterine cancer Rate per 100,000 population Mortality of Uterine cancer among Females, by Health Zone, Queensland, 1986 to 2002 Northern Central Southern 0 3 6 9 12 15 Year 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Note: Rates are age standardised to the Australian population as at 30 June 2001. Data are reported by place of usual residence and year of diagnosis. Uterine cancer is defined by the ICD-0-2 codes of C54 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by Epidemiology Services Unit, Queensland Health For more information: Health Status Indicators for Queensland ...

Cancer Incidence by Proportion Indigenous Population in Queensland Uterine cancer 0 3 6 9 12 15 18 Rate per 100,000 population Avg No. per Year Incidence of Uterine cancer among Females, by Indigenous Proportion, Queensland, Five Year Average, 1998 to 2002 16.3 261 <5% Indigenous Proportion Indigenous Population 14.1 21 At least 5% Indigenous Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 . Source: Queensland Cancer Registry, Queensland Health and Queensland ...

Cancer Mortality by Socioeconomic Status in Queensland Uterine cancer 0 3 6 9 12 15 Rate per 100,000 population Avg No. per Year Mortality of Uterine cancer among Females, by SEIFA category, Queensland, Five Year Average, 1998 to 2002 3.0 7 High SES SEIFA Quintile 2.9 10 Mod. high SES 2.2 8 Moderate SES 2.6 13 Mod. Low SES 3.0 11 Low SES Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 . Source: Queensland ...

Trends in Cancer Incidence in Queensland Uterine cancer Rate per 100,000 population Incidence of Uterine cancer , among Females, Queensland, 1982 to 2002 Female 0 3 6 9 12 15 18 Year 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 Note: Rates are age standardised to the Australian population as at 30 June 2001. Data are reported by year of diagnosis. Uterine cancer is defined by the ICD-0-2 codes of C54 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by Epidemiology Services Unit, Queensland Health For more information: Health Status Indicators for Queensland Queensland Health Cancer Publications (http://www.health.qld.gov.au/hic/default.asp) Queensland Cancer Fund (http...

Cancer Incidence by Geographical Reporting Area in Queensland Uterine cancer 0 3 6 9 12 15 18 21 24 Rate per 100,000 population Avg No. per Year Incidence of Uterine cancer among Females, by Geographical Reporting Area, Queensland, Five Year Average, 1998 to 2002 16.1 14 Bayside Geographical Area 17.9 46 Brisbane North 16.9 35 Brisbane South 18.3 23 Darling Downs/Sth West 14.4 13 Far North 17.7 15 Fitzroy/Central West 12.7 26 Gold Coast 14.8 16 Logan-Beaudesert 16.4 8 Mackay 13.8 13 Northern/North West 16.7 15 Redcliffe-Caboolture 13.6 19 Sunshine Coast 17.7 ...

Cancer Incidence by Socioeconomic Status in Queensland Uterine cancer 0 3 6 9 12 15 18 21 Rate per 100,000 population Avg No. per Year Incidence of Uterine cancer among Females, by SEIFA category, Queensland, Five Year Average, 1998 to 2002 16.4 39 High SES SEIFA Quintile 16.3 57 Mod. high SES 14.8 52 Moderate SES 15.5 72 Mod. Low SES 17.7 63 Low SES Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 . Source: ...

Age Sex Site Diagnosis pTNM Stage 1 70 F cervix squamous cell carcinoma T1aN0M0 I 2 46 F cervix squamous cell carcinoma T1a1N0M0 IA1 3 42 F cervix microinvasive squamous cell carcinoma T1a1N0M0 IA1 4 57 F cervix squamous cell carcinoma in situ TisN0M0 0 5 33 F cervix microinvasive squamous cell carcinoma T1a1N0M0 IA1 6 35 F cervix squamous cell carcinoma in situ TisN0M0 0 7 48 F cervix microinvasive squamous cell carcinoma T1a1N0M0 IA1 8 39 F cervix microinvasive squamous cell carcinoma T1N0M0 I 9 58 F cervix microinvasive squamous cell carcinoma T1N0M0 I 10 53 F cervix squamous cell carcinoma in situ TisN0M0 ...

SUSWORO ET AL 2 RADIATION MEDICINE R E V I E W Radiation Medicine: Vol. 22 No. 1, 2–5 p.p., 2004 HDR Interstitial Perineal Implant for Locally Advanced or Recurrent Uterine Cervix Cancer Raden Susworo, Nana Supriana, and Irwan Ramli Purpose: To evaluate whether high-dose-rate (HDR) interstitial perineal implants can effectively eradicate residual tumor or recurrent tumor in uterine cervix cancer after complete radiation treatment. Materials and Methods: This method of treatment was commenced in January 2002, and four advanced stage and four uterine cervix cancer (UCC) recurrences were admitted for this study. All untreated stage II bulky mass and IIIB patients received 50 Gy external beam radiotherapy (EBR) to the whole pelvis prior to the interstitial perineal implant. No EBR was given to recurrent UCC. Brachytherapy was delivered using Martinez ...

305 Volume 17, Number 4 ORIGINAL ARTICLE ORIGINAL ARTICLE Radiation Medicine: Vol.17 No.4, 305–309 p.p., 1999 Angiographic Changes in Uterine Cervical Cancer during the Course of Transarterial Infusion Chemotherapy Hidekazu Saitoh,* Yasushi Nagata,* Michihide Mitsumori,* Masaki Kokubo,* and Masahiro Hiraoka* Purpose: To assess the correlation between angiographic findings, tumor stage, tumor size, histological type, and the effect of transcatheter arterial infusion (TAI) chemotherapy in patients with uterine cervical cancer . Materials and Methods: Thirty-three patients with untreated cervical cancer underwent two cycles of TAI. Changes in angiographic findings and other clinical and imaging data were assessed using the ? 2 test, multivariate analysis, and the two-sample t-test. Results: The group with parametric involvement included more ...

299 Cad. Saúde Pública, Rio de Janeiro, 21(1):299-309, jan-fev, 2005 ARTIGO ARTICLE Evolution of uterine cervical cancer mortality from 1979 to 1998 in the State of Rio Grande do Sul, Brazil A evolução da mortalidade por câncer de colo de útero entre 1979 e 1998 no Rio Grande do Sul, Brasil 1 Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil. 2 Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil. Correspondence L. Kalakun Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul. Rua Ramiro Barcelos 2350, Porto Alegre, RS 90035-903, Brasil. lkalakun@hcpa.ufrgs.br Luciane Kalakun 1 Mary Clarisse Bozzetti ...

Composite hat Women Need to Know • Other things that increase your risk for uterine cancer include: diabetes gall bladder disease high blood pressure being overweight • One way to reduce the added risk from estrogen replacement therapy is to add the hormone progesterone to the therapy. • Getting pregnant or using birth control pills appear to protect against cancer of the uterus lining. • Some women with a family history of colon cancer also may be more likely to get ovarian cancer and cancer of the lining of the uterus. How can I detect uterine cancer early? • Women 40 and over should get an annual pelvic exam. Younger women should have a pelvic exam at the same time as their Pap test for cervical cancer . • Women at high risk for uterine cancer should get a special ...

U NITED S TATES D ISTRICT C OURT FOR THE D ISTRICT OF M ASSACHUSETTS QUESTIONS ? CALL 1-866-410-7650 TOLL FREE , OR VISIT WWW . LUPRONCLAIMS . COM P ARA UNA NOTIFICACIÓN EN ESPAÑOL , VISITE NUESTRO SITIO DE INTERNET - 1 - If you paid for Lupron ® —used to treat prostate cancer , endometriosis, uterine fibroids, and precocious puberty—you could get a payment from a legal settlement. A federal court authorized this notice. This is not a solicitation from a lawyer. • A nationwide settlement has been proposed in class action litigation about the cost of Lupron ® . This notice is for: o Consumers who paid for Lupron ® ...

If you paid for Lupron ® —used to treat prostate cancer , endometriosis, uterine fibroids, and precocious puberty—you could get a payment from a legal settlement. www.lupronclaims.com 1-866-410-7650 I declare that the information here is true and correct. If not submitting this for myself, I am authorized to submit this form on behalf of the patient above. Your Name Your Address Your City, State, Zip Name of Lupron ® Patient / Relationship to you Signature Date I’d like a payment from the Lupron ® settlement. Complete and mail to the address below, postmarked by May 15, 2005 . Mail by May 15, 2005 to: Lupron Settlement Administrator P.O. Box 24604 West Palm Beach, FL 33416 Dates You or Patient took Lupron ® (Month/Year - Month/Year) Name of Doctor ...

REG-8 REG-7 REG-6 REG-5 REG-4 REG-3 REG-2 REG-1 WYOMING ORLEANS NIAGARA GENESEE ERIE CHAUTAUQUA CATTARAUGUS ALLEGANY YATES *** WAYNE STEUBEN SENECA *** SCHUYLER *** ONTARIO MONROE LIVINGSTON CHEMUNG TOMPKINS ST. LAWRENCE OSWEGO ONONDAGA ONEIDA MADISON LEWIS *** JEFFERSON HERKIMER CORTLAND CAYUGA TIOGA CHENANGO BROOME WASHINGTON WARREN SCHOHARIE SCHENECTADY SARATOGA RENSSELAER OTSEGO *** MONTGOMERY *** HAMILTON GREENE FULTON FRANKLIN ESSEX *** DELAWARE COLUMBIA CLINTON ALBANY WESTCHESTER ULSTER SULLIVAN ROCKLAND PUTNAM ORANGE DUTCHESS RICHMOND QUEENS NEW YORK KINGS BRONX SUFFOLK NASSAU INCIDENCE RATE 0 1 ...

Survival prediction using artificial neural networks in patients with uterine cervical cancer Masahiro Iinuma, Kenya Murase Department of Medical Physics and Engineering, Graduate School of Medicine, Osaka University, Osaka, Japan Abstract Our purpose of this study was to construct the predict model using artificial neural networks (ANNs) from radiation oncology database. Although there is no guarantee that trained ANNs models reached an error minimum point, we made 40 models by each combination of hidden nodes (30, 50, 100, and 150). Using the trained ANNs, we predicted the survival in patients with uterine cervical cancer treated by radiation therapy. The performance of ANNs was evaluated using receiver operating characteristic (ROC) analysis by those maximums and the mean. Az value was the highest at the number of neuron 150, and the value was maximum ...

44 TABLE 21. ENDOMETRIAL ( UTERINE CORPUS) CANCER INCIDENCE BY COUNTY, WHITE FEMALES, NEW JERSEY - 1986-1996 1 COUNTY 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 (Prelim.) No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate Atlantic 24 19.9 26 22.6 23 17.4 15 14.2 27 22.9 33 24.5 30 24.2 37 31.2 35 27.9 26 21.4 22 18.0 Bergen 123 20.6 136 24.1 121 20.6 115 20.2 98 16.7 161 29.2 135 23.9 125 22.3 139 24.6 126 22.6 138 23.9 Burlington 26 13.7 41 22.1 31 15.9 40 19.2 42 21.3 38 19.3 35 18.0 59 28.9 57 26.8 57 28.2 47 22.3 Camden 50 18.8 43 15.1 50 19.3 61 22.2 61 23.0 61 23.8 55 21.9 45 18.3 55 22.0 ...

Cancer Research and Treatment 2003;35(6):549-556 1 INTRODUCTION Photodynamic therapy (PDT) is principally a new method of treating malignant tumors, based on the use of photodynamical damage of tumor cells under a photochemical reaction (1~3). During the last several years, a whole range of dyes, such as Photofrin (Axcan Scandipharm Inc., Birmingham, AL), HPD (Beijing Institute of Pharmaceutical, Beijing, China), Photogem (TimTec Corp., Newark, DE), Benzoporphyrin derivative (QLT Inc., Vancouver, Canada), 5-aminolevulenic acid (PhotoCure Inc., Oslo, Norway) and others, have been used as photosen- sitizers for a wide range of malignant tumors, as well as non-malignant diseases (4~6). A tumor treated by PDT was resorbed, and gradually substituted by connecting tissues. The locality of photodynamic damage of a tumor is provided by the ability of a photosensitizer to accumulate in ...

Body of uterus Cancer survival, incidence and mortality in NSW 1994–2000 42 The Cancer Council NSW Uterine cancer • The five-year relative survival from uterine cancer in NSW between 1994 and 2000 was 79.8% • No Area Health Service was different from the State average in the adjusted relative risk of excess death after shrinking • An additional 14 patients would be expected to survive to five years after diagnosis in NSW if the State average risk was shifted to the 20 th centile of the distribution • There were 2,179 new cases of uterine cancer in NSW in 1994 to 1998 and 469 deaths • There were no Area Health Services in which the number of new cases of uterine cancer was different from expected, and there was no area variation in the excess number of deaths from uterine cancer Table 19a: Five-year relative survival, relative risk of excess ...

Uterine cancer The uterus (womb) is part of the female reproductive system. It is shaped like an upside down pear and sits inside the pelvis. It is in the uterus that a fertilised egg grows into a baby. Over 470 Victorian women are diagnosed with cancer of the uterus every year. Most of these women are over the age of 50 years. Cancer of the uterus is also known as cancer of the womb, uterine cancer , endometrial cancer and cancer of the lining of the womb. Different types Most cases of cancer of the uterus are cancers of the uterus lining (endometrium), though some cancers grow in the muscle layers of the uterus. The different types of uterine cancer include: • Adenocarcinoma of the endometrium - around 85 per cent of women diagnosed with cancer of the uterus have this form. An adenocarcinoma is a cancer that starts in ...

Abstract. Lumican is a member of a small leucine-rich proteoglycan (SLRP) family and is reported to be over- expressed during the wound healing process of the cornea, and ischemic and reperfused heart. In the carcinomatous tissues, lumican is overexpressed in human breast and pancreatic cancer tissues. In the present study, we aimed to clarify the expression of lumican mRNA and its protein in human cervical cancer cell lines (CaSki, ME-180 and HeLa cells) and their localization in normal and cancerous human cervical tissues. Reverse transcription-polymerase chain reaction and Western blot analysis revealed the expression of lumican mRNA and its protein in CaSki, ME-180 and HeLa cells. No or weak immunoreactivity of the lumican protein was observed in stroma but not in squamous and ductal cells of non-cancerous uterine cervical tissues. In 21 of 28 (75%) cervical cancer cases, the lumican protein ...

Abstract. The development of carcinoma is associated with alterations in the expression of many cell adhesion molecules. Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and changes its expression following malignant transformation in some tumors. Our purpose was to examine the pattern of syndecan-1 expression in cancer of the uterine cervix and assess the clinicopathological significance of syndecan-1 expression. A total of 106 tissue specimens (6 normal, 19 cervical intraepithelial neoplasia (CIN) and 81 invasive cancer ) were analyzed immunohistochemically. In addition, the corresponding expression of mRNA in tumor tissues was evaluated by reverse transcription-polymerase chain reaction (RT/PCR) in comparison with normal counterparts. Syndecan-1 was positive in normal squamous cells except the basal cell layer. The intensity of syndecan-1 staining was ...

All-Ireland cancer statistics 1994-96 69 Uterine cervix 14. MALIGNANT CANCER OF THE UTERINE CERVIX ICD-O.2 C53 ICD-10 C53 ICD-9 180 Key facts • Average of 259 new cases (105 deaths) per year, 1994-96. • 10th most common site for cancer incidence, and 10th most common cause of cancer deaths, in females. • Median age at diagnosis 46 years, much lower than for cancers as a whole. • Incidence rates about 25% higher in urban compared with other populations. • Incidence rates below average for the EU. Summary statistics Table 14.1 Incidence 1994-96 On average each year, 259 new cases of malignant cervical cancer were diagnosed in Ireland. This was the tenth most common site of malignant cancer in women. On average, Irish women were estimated to have a 1-in-120 chance of developing the malignant ...

51 T he presence of simultaneous carcinomas involving both the ovary and uterine corpus is rel- atively uncommon, and only 0.7–10% of patients with epithelial ovarian or uterine cancers have been found to have simultaneous tumours in large series. 1 However, these synchronous tumours represent a diagnostic and ther- apeutic challenge, particularly if they have a similar histol- ogy. Here we present the case of a 34-year-old woman with endometrioid cancers of both ovaries and adenocarcinoma of the uterus. C A S E RE POR T The patient was referred to our hospital because of metror- rhagia and lower abdominal pain of six months duration. She had started to menstruate at the age of 14 and her periods were irregular, occurring every 2–3 months, but with no associated abdominal pain. Five years earlier she had a spontaneous abortion during the12 ...

Relationship of Leukemia Risk to Radiation Dose Following Cancer of the Uterine Corpus Rochelle E. Curtis, John D. Boice, Jr., Marilyn Stovall, Leslie Bernstein, Eric Holowaty, Sakari Karjalainen, Froydis Langmark, Philip C. Nasca, Ann G. Schwartz, Maria J. Schymura, Hans H. Storm, Peter Toogood, Peter Weyer, William C. Moloney* Background: Radiotherapy has been linked infrequently to secondary leukemia despite extensive exposure of the active bone marrow to ionizing radiation. Few studies include sub- stantial numbers of elderly patients. Purpose: We evaluated women with cancer of the uterine corpus, the majority of whom were treated at older ages, to gain additional informa- tion on cancer risk following partial-body radiotherapy and to examine differences in risk between external-beam therapy and brachytherapy. Methods: A cohort of 110000 women with ...

Low-cost technology for screening uterine cervical cancer V AdityaParashari, 1 VeenaSingh, 2 AshokSehgal, 3 Labani Satyanarayana, 4 PushpaSodhani, 4 &MadanM. Gupta 2 We report on an illuminated, low-cost (Rs 1500 (US$ 36)) magnifying device (Magnivisualizer) for detecting precancerous lesions of the uterine cervix. A total of 403 women attending a maternal and child health care clinic who had abnormal vaginal discharge and related symptoms were referred for detailed pelvic examination and visual inspection by means of the device after the application of 5% (v/v) acetic acid. Pap smears were obtained at the same time. The results were compared with those obtained using colposcopy and/or histology. The Magnivisualizer improved the detection rate of early cancerous lesions from 60%, for unaided visual inspection, ...

REVIEW ARTICLE CURRENT SCIENCE, VOL. 78, NO. 1, 10 JANUARY 2000 52 Cancer of the uterine cervix and human papillomavirus infection B. C. Das*, V. Gopalkrishna, Suresh Hedau and Sanjay Katiyar Division of Molecular Oncology, Institute of Cytology and Preventive Oncology (ICMR), Maulana Azad Medical College Campus, Bahadur Shah Zafar Marg, New Delhi 110 002, India Human papillomaviruses (HPVs) have emerged as the principal sexually transmitted causal agents in the development of cancer of the uterine cervix in women. They also cause a variety of benign lesions, warts, intraepithelial neoplasia and anogenital, oral and pharyngeal papillomas. Presently, more than 100 HPV genotypes have been identified in humans, and about one-third of them have been sequenced. Of these, while HPV types 16 and 18 are considered to be the high-risk types, HPV 6 and 11 ...

Dynamic contrast-enhanced MR imaging of uterine cervical cancer : pharmacokinetic analysis with histologic correlation and its prognostic significance after radiation therapy Yasuyuki Yamashita M. D. ’, Takashi Baba M. D. l, Yuji Baba M. D. ‘, Ryuichi Nishimura M. D. l, Mutsumasa Takahashi M. D. l, Hitoshi Okamura M. D.2 Department of lRadiology, 20bsterics and Gynecology , Kumamoto University School of Medicine, l-l-l Honjo Kumamoto 860-8556, Japan Purpose It has been shown that dynamic MR imaging of cervical cancer may predict tumor control with radiation therapy. This study investigated pathologic and pharmacokinetic basis of different enhancement patterns on dynamic MR imaging with advanced cervical cancer by correlating imaging findings with histopathologic findings and results of radiation therapy. Methods and Materials The correlation between dynamic MR ...

45 ENDOMETRIAL ( UTERINE CORPUS) CANCER INCIDENCE BY COUNTY, BLACK FEMALES, NEW JERSEY - 1986-1990 AND 1991-1996 1 COUNTY 1986-1990 1991-1996 Number Rate Number Rate 2 2 Atlantic 13 11.4 21 13.4 Bergen 15 14.1 29 18.8 Burlington 11 10.1 28 20.9 Camden 25 13.6 35 14.4 Cumberland 15 30.0 6 8.3 Essex 115 14.7 146 14.6 Gloucester 5 8.9 10 14.0 Hudson 25 15.6 44 20.1 Mercer 21 14.3 28 14.2 Middlesex 8 9.5 24 18.4 Monmouth 21 16.3 27 15.0 Morris --- --- 8 19.1 Ocean --- --- 7 23.3 Passaic 19 14.8 29 15.6 Salem --- --- ...